Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
Background Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene–related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including p...
Gespeichert in:
| Veröffentlicht in: | Headache 2025-01, Vol.65 (1), p.143-152 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 152 |
|---|---|
| container_issue | 1 |
| container_start_page | 143 |
| container_title | Headache |
| container_volume | 65 |
| creator | Wang, Shuu‐Jiun Kim, Byung‐Kun Wang, Hebo Zhou, Jiying Wan, Qi Yu, Tingmin Lian, Yajun Arkuszewski, Michal Ecochard, Laurent Snellman, Josefin Wen, Shihua Yin, Fangfang Li, Zheng Su, Wendy Yu, Shengyuan |
| description | Background
Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene–related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date.
Objective
Primary results of the DRAGON study demonstrated the efficacy and safety of erenumab in patients with CM from China and other Asian countries. This post hoc analysis evaluated the rate of reversion from CM to EM in the overall population and in subgroups of patients defined by baseline demographic and clinical characteristics (age, body mass index, gender, prior preventive treatment failure, medication overuse status, and disease duration).
Methods
Reversion from CM to EM was defined as a reduction in headache frequency to |
| doi_str_mv | 10.1111/head.14733 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3060380352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3154577923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2463-7002846f941ee129d66eddc21c9048c11d2d58851f5e9168a518234ae4f2f1033</originalsourceid><addsrcrecordid>eNp9kc9qFTEUh4Mo9lrd-AAScCPC1PyfjLuhvbZCaUF0PaTJiTdlZjImM8p9CZ_ZjLeW4qJZnHBOPr5D-CH0mpITWs6HHRh3QkXN-RO0oZKpSihKnqINIbSudC30EXqR8y0hRKhGPUdHXNda8oZv0O-t92BnHD2GBOMymBscRzzvACf4CSmH0vkUB2x3KY7B4iF8TyaMgOeIYQo5uofDMGIz4jaHUqc4Lb2Zi-EjbkuXZ7yLtrybfp9DXneue86-tOfXVzjPi9u_RM-86TO8uruP0bdP26-nF9Xl9fnn0_ayskwoXtWEMC2UbwQFoKxxSoFzllHbEKEtpY45qbWkXkJDlTaSasaFAeGZp4TzY_Tu4J1S_LFAnrshZAt9b0aIS-44UYRrwiUr6Nv_0Nu4pPKHQlEpZF03bBW-P1A2xZwT-G5KYTBp31HSrSl1a0rd35QK_OZOudwM4O7Rf7EUgB6AX6GH_SOq7mLbnh2kfwCpHpuZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3154577923</pqid></control><display><type>article</type><title>Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wang, Shuu‐Jiun ; Kim, Byung‐Kun ; Wang, Hebo ; Zhou, Jiying ; Wan, Qi ; Yu, Tingmin ; Lian, Yajun ; Arkuszewski, Michal ; Ecochard, Laurent ; Snellman, Josefin ; Wen, Shihua ; Yin, Fangfang ; Li, Zheng ; Su, Wendy ; Yu, Shengyuan</creator><creatorcontrib>Wang, Shuu‐Jiun ; Kim, Byung‐Kun ; Wang, Hebo ; Zhou, Jiying ; Wan, Qi ; Yu, Tingmin ; Lian, Yajun ; Arkuszewski, Michal ; Ecochard, Laurent ; Snellman, Josefin ; Wen, Shihua ; Yin, Fangfang ; Li, Zheng ; Su, Wendy ; Yu, Shengyuan</creatorcontrib><description>Background
Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene–related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date.
Objective
Primary results of the DRAGON study demonstrated the efficacy and safety of erenumab in patients with CM from China and other Asian countries. This post hoc analysis evaluated the rate of reversion from CM to EM in the overall population and in subgroups of patients defined by baseline demographic and clinical characteristics (age, body mass index, gender, prior preventive treatment failure, medication overuse status, and disease duration).
Methods
Reversion from CM to EM was defined as a reduction in headache frequency to < 45 headache days over the 12 weeks of the double‐blind treatment period. In addition, migraine‐related disability and disease impact on functional impairment were assessed within each treatment group in reverters and non‐reverters using the Headache Impact Test‐6 (HIT‐6), Migraine Physical Function Impact Diary (MPFID), and modified Migraine Disability Assessment (mMIDAS).
Results
Overall, 557 patients with CM were randomized to monthly erenumab 70 mg (n = 279) or placebo (n = 278), of whom 52.3% (146 of 279) treated with erenumab reverted from CM to EM compared to 41.0% (114 of 278) in the placebo group (odds ratio [OR] 1.59, 95% confidence interval: 1.1–2.2; p = 0.007). Treatment with erenumab resulted in a greater mean change (standard error) from baseline in the HIT‐6 total score for reverters versus non‐reverters compared to placebo (erenumab: −9.5 [0.6] vs. −5.1 [0.5]; placebo: −8.9 [0.7] vs. −4.9 [0.5]). A similar pattern was observed for mMIDAS score in erenumab treatment groups versus placebo (erenumab: −22.1 [1.2] vs. −6.3 [1.8]; placebo: −19.9 [1.3] vs. −7.9 [1.6]). Substantial improvements were reported in MPFID‐Physical Impairment (PI) and Everyday Activities (EA) scores in reverters versus non‐reverters in erenumab treatment groups (MPFID‐PI: −5.9 [0.3] vs. −1.9 [0.6]; MPFID‐EA: −7.9 [0.4] vs. −3.4 [0.6]) and in placebo (MPFID‐PI: −5.4 [0.4] vs. −1.0 [0.5]; MPFID‐EA: −7.1 [0.5] vs. −3.2 [0.5]).
Conclusions
This analysis demonstrated that a greater proportion of patients treated with erenumab reverted from CM to EM compared to patients treated with placebo. The reversion from CM to EM was reflected by the greater improvements in patient‐reported outcomes in the erenumab group.
Plain Language Summary
Chronic migraine (CM) represents a greater burden to patients with migraine; thus, conversion from CM to episodic migraine (EM) by reducing the frequency of monthly headache days can be a good indicator of how well migraine treatment is working. This study evaluated the rate of conversion from CM to EM in two groups of patients, in which one group received erenumab and the other group received placebo. This study showed that more patients in the erenumab group changed from CM to EM and reported improvement in daily activities compared to the placebo group.</description><identifier>ISSN: 0017-8748</identifier><identifier>ISSN: 1526-4610</identifier><identifier>EISSN: 1526-4610</identifier><identifier>DOI: 10.1111/head.14733</identifier><identifier>PMID: 38785393</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - pharmacology ; Asia ; Asian People ; Body mass index ; Body size ; Calcitonin ; Calcitonin Gene-Related Peptide Receptor Antagonists - administration & dosage ; Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology ; calcitonin gene–related peptide ; Chronic Disease ; Clinical trials ; Double-Blind Method ; Effectiveness ; erenumab ; Female ; Headache ; Headaches ; Health services ; Humans ; Impact tests ; Impairment ; Male ; Middle Aged ; Migraine ; Migraine Disorders - drug therapy ; Monoclonal antibodies ; Outcome Assessment, Health Care ; Patients ; patient‐reported outcomes ; Placebos ; Population studies ; reversion rate ; Standard error ; Subgroups</subject><ispartof>Headache, 2025-01, Vol.65 (1), p.143-152</ispartof><rights>2024 American Headache Society.</rights><rights>2025 American Headache Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2463-7002846f941ee129d66eddc21c9048c11d2d58851f5e9168a518234ae4f2f1033</cites><orcidid>0000-0001-8933-088X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhead.14733$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhead.14733$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38785393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Shuu‐Jiun</creatorcontrib><creatorcontrib>Kim, Byung‐Kun</creatorcontrib><creatorcontrib>Wang, Hebo</creatorcontrib><creatorcontrib>Zhou, Jiying</creatorcontrib><creatorcontrib>Wan, Qi</creatorcontrib><creatorcontrib>Yu, Tingmin</creatorcontrib><creatorcontrib>Lian, Yajun</creatorcontrib><creatorcontrib>Arkuszewski, Michal</creatorcontrib><creatorcontrib>Ecochard, Laurent</creatorcontrib><creatorcontrib>Snellman, Josefin</creatorcontrib><creatorcontrib>Wen, Shihua</creatorcontrib><creatorcontrib>Yin, Fangfang</creatorcontrib><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Su, Wendy</creatorcontrib><creatorcontrib>Yu, Shengyuan</creatorcontrib><title>Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study</title><title>Headache</title><addtitle>Headache</addtitle><description>Background
Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene–related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date.
Objective
Primary results of the DRAGON study demonstrated the efficacy and safety of erenumab in patients with CM from China and other Asian countries. This post hoc analysis evaluated the rate of reversion from CM to EM in the overall population and in subgroups of patients defined by baseline demographic and clinical characteristics (age, body mass index, gender, prior preventive treatment failure, medication overuse status, and disease duration).
Methods
Reversion from CM to EM was defined as a reduction in headache frequency to < 45 headache days over the 12 weeks of the double‐blind treatment period. In addition, migraine‐related disability and disease impact on functional impairment were assessed within each treatment group in reverters and non‐reverters using the Headache Impact Test‐6 (HIT‐6), Migraine Physical Function Impact Diary (MPFID), and modified Migraine Disability Assessment (mMIDAS).
Results
Overall, 557 patients with CM were randomized to monthly erenumab 70 mg (n = 279) or placebo (n = 278), of whom 52.3% (146 of 279) treated with erenumab reverted from CM to EM compared to 41.0% (114 of 278) in the placebo group (odds ratio [OR] 1.59, 95% confidence interval: 1.1–2.2; p = 0.007). Treatment with erenumab resulted in a greater mean change (standard error) from baseline in the HIT‐6 total score for reverters versus non‐reverters compared to placebo (erenumab: −9.5 [0.6] vs. −5.1 [0.5]; placebo: −8.9 [0.7] vs. −4.9 [0.5]). A similar pattern was observed for mMIDAS score in erenumab treatment groups versus placebo (erenumab: −22.1 [1.2] vs. −6.3 [1.8]; placebo: −19.9 [1.3] vs. −7.9 [1.6]). Substantial improvements were reported in MPFID‐Physical Impairment (PI) and Everyday Activities (EA) scores in reverters versus non‐reverters in erenumab treatment groups (MPFID‐PI: −5.9 [0.3] vs. −1.9 [0.6]; MPFID‐EA: −7.9 [0.4] vs. −3.4 [0.6]) and in placebo (MPFID‐PI: −5.4 [0.4] vs. −1.0 [0.5]; MPFID‐EA: −7.1 [0.5] vs. −3.2 [0.5]).
Conclusions
This analysis demonstrated that a greater proportion of patients treated with erenumab reverted from CM to EM compared to patients treated with placebo. The reversion from CM to EM was reflected by the greater improvements in patient‐reported outcomes in the erenumab group.
Plain Language Summary
Chronic migraine (CM) represents a greater burden to patients with migraine; thus, conversion from CM to episodic migraine (EM) by reducing the frequency of monthly headache days can be a good indicator of how well migraine treatment is working. This study evaluated the rate of conversion from CM to EM in two groups of patients, in which one group received erenumab and the other group received placebo. This study showed that more patients in the erenumab group changed from CM to EM and reported improvement in daily activities compared to the placebo group.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - pharmacology</subject><subject>Asia</subject><subject>Asian People</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Calcitonin</subject><subject>Calcitonin Gene-Related Peptide Receptor Antagonists - administration & dosage</subject><subject>Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology</subject><subject>calcitonin gene–related peptide</subject><subject>Chronic Disease</subject><subject>Clinical trials</subject><subject>Double-Blind Method</subject><subject>Effectiveness</subject><subject>erenumab</subject><subject>Female</subject><subject>Headache</subject><subject>Headaches</subject><subject>Health services</subject><subject>Humans</subject><subject>Impact tests</subject><subject>Impairment</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Monoclonal antibodies</subject><subject>Outcome Assessment, Health Care</subject><subject>Patients</subject><subject>patient‐reported outcomes</subject><subject>Placebos</subject><subject>Population studies</subject><subject>reversion rate</subject><subject>Standard error</subject><subject>Subgroups</subject><issn>0017-8748</issn><issn>1526-4610</issn><issn>1526-4610</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9qFTEUh4Mo9lrd-AAScCPC1PyfjLuhvbZCaUF0PaTJiTdlZjImM8p9CZ_ZjLeW4qJZnHBOPr5D-CH0mpITWs6HHRh3QkXN-RO0oZKpSihKnqINIbSudC30EXqR8y0hRKhGPUdHXNda8oZv0O-t92BnHD2GBOMymBscRzzvACf4CSmH0vkUB2x3KY7B4iF8TyaMgOeIYQo5uofDMGIz4jaHUqc4Lb2Zi-EjbkuXZ7yLtrybfp9DXneue86-tOfXVzjPi9u_RM-86TO8uruP0bdP26-nF9Xl9fnn0_ayskwoXtWEMC2UbwQFoKxxSoFzllHbEKEtpY45qbWkXkJDlTaSasaFAeGZp4TzY_Tu4J1S_LFAnrshZAt9b0aIS-44UYRrwiUr6Nv_0Nu4pPKHQlEpZF03bBW-P1A2xZwT-G5KYTBp31HSrSl1a0rd35QK_OZOudwM4O7Rf7EUgB6AX6GH_SOq7mLbnh2kfwCpHpuZ</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Wang, Shuu‐Jiun</creator><creator>Kim, Byung‐Kun</creator><creator>Wang, Hebo</creator><creator>Zhou, Jiying</creator><creator>Wan, Qi</creator><creator>Yu, Tingmin</creator><creator>Lian, Yajun</creator><creator>Arkuszewski, Michal</creator><creator>Ecochard, Laurent</creator><creator>Snellman, Josefin</creator><creator>Wen, Shihua</creator><creator>Yin, Fangfang</creator><creator>Li, Zheng</creator><creator>Su, Wendy</creator><creator>Yu, Shengyuan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8933-088X</orcidid></search><sort><creationdate>202501</creationdate><title>Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study</title><author>Wang, Shuu‐Jiun ; Kim, Byung‐Kun ; Wang, Hebo ; Zhou, Jiying ; Wan, Qi ; Yu, Tingmin ; Lian, Yajun ; Arkuszewski, Michal ; Ecochard, Laurent ; Snellman, Josefin ; Wen, Shihua ; Yin, Fangfang ; Li, Zheng ; Su, Wendy ; Yu, Shengyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2463-7002846f941ee129d66eddc21c9048c11d2d58851f5e9168a518234ae4f2f1033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - pharmacology</topic><topic>Asia</topic><topic>Asian People</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Calcitonin</topic><topic>Calcitonin Gene-Related Peptide Receptor Antagonists - administration & dosage</topic><topic>Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology</topic><topic>calcitonin gene–related peptide</topic><topic>Chronic Disease</topic><topic>Clinical trials</topic><topic>Double-Blind Method</topic><topic>Effectiveness</topic><topic>erenumab</topic><topic>Female</topic><topic>Headache</topic><topic>Headaches</topic><topic>Health services</topic><topic>Humans</topic><topic>Impact tests</topic><topic>Impairment</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Monoclonal antibodies</topic><topic>Outcome Assessment, Health Care</topic><topic>Patients</topic><topic>patient‐reported outcomes</topic><topic>Placebos</topic><topic>Population studies</topic><topic>reversion rate</topic><topic>Standard error</topic><topic>Subgroups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Shuu‐Jiun</creatorcontrib><creatorcontrib>Kim, Byung‐Kun</creatorcontrib><creatorcontrib>Wang, Hebo</creatorcontrib><creatorcontrib>Zhou, Jiying</creatorcontrib><creatorcontrib>Wan, Qi</creatorcontrib><creatorcontrib>Yu, Tingmin</creatorcontrib><creatorcontrib>Lian, Yajun</creatorcontrib><creatorcontrib>Arkuszewski, Michal</creatorcontrib><creatorcontrib>Ecochard, Laurent</creatorcontrib><creatorcontrib>Snellman, Josefin</creatorcontrib><creatorcontrib>Wen, Shihua</creatorcontrib><creatorcontrib>Yin, Fangfang</creatorcontrib><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Su, Wendy</creatorcontrib><creatorcontrib>Yu, Shengyuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Headache</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Shuu‐Jiun</au><au>Kim, Byung‐Kun</au><au>Wang, Hebo</au><au>Zhou, Jiying</au><au>Wan, Qi</au><au>Yu, Tingmin</au><au>Lian, Yajun</au><au>Arkuszewski, Michal</au><au>Ecochard, Laurent</au><au>Snellman, Josefin</au><au>Wen, Shihua</au><au>Yin, Fangfang</au><au>Li, Zheng</au><au>Su, Wendy</au><au>Yu, Shengyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study</atitle><jtitle>Headache</jtitle><addtitle>Headache</addtitle><date>2025-01</date><risdate>2025</risdate><volume>65</volume><issue>1</issue><spage>143</spage><epage>152</epage><pages>143-152</pages><issn>0017-8748</issn><issn>1526-4610</issn><eissn>1526-4610</eissn><abstract>Background
Erenumab is a fully human monoclonal antibody that selectively targets the calcitonin gene–related peptide receptor. It has been proven to be safe and efficacious in patients with episodic migraine (EM) and chronic migraine (CM) as demonstrated in phase 2 and 3 clinical trials including patients from Europe, Japan, and the United States. Reversion from CM to EM, as indicated by a reduction in the frequency of headache days, is an important indicator for efficacy outcome, though it has not been analyzed widely in patients with CM to date.
Objective
Primary results of the DRAGON study demonstrated the efficacy and safety of erenumab in patients with CM from China and other Asian countries. This post hoc analysis evaluated the rate of reversion from CM to EM in the overall population and in subgroups of patients defined by baseline demographic and clinical characteristics (age, body mass index, gender, prior preventive treatment failure, medication overuse status, and disease duration).
Methods
Reversion from CM to EM was defined as a reduction in headache frequency to < 45 headache days over the 12 weeks of the double‐blind treatment period. In addition, migraine‐related disability and disease impact on functional impairment were assessed within each treatment group in reverters and non‐reverters using the Headache Impact Test‐6 (HIT‐6), Migraine Physical Function Impact Diary (MPFID), and modified Migraine Disability Assessment (mMIDAS).
Results
Overall, 557 patients with CM were randomized to monthly erenumab 70 mg (n = 279) or placebo (n = 278), of whom 52.3% (146 of 279) treated with erenumab reverted from CM to EM compared to 41.0% (114 of 278) in the placebo group (odds ratio [OR] 1.59, 95% confidence interval: 1.1–2.2; p = 0.007). Treatment with erenumab resulted in a greater mean change (standard error) from baseline in the HIT‐6 total score for reverters versus non‐reverters compared to placebo (erenumab: −9.5 [0.6] vs. −5.1 [0.5]; placebo: −8.9 [0.7] vs. −4.9 [0.5]). A similar pattern was observed for mMIDAS score in erenumab treatment groups versus placebo (erenumab: −22.1 [1.2] vs. −6.3 [1.8]; placebo: −19.9 [1.3] vs. −7.9 [1.6]). Substantial improvements were reported in MPFID‐Physical Impairment (PI) and Everyday Activities (EA) scores in reverters versus non‐reverters in erenumab treatment groups (MPFID‐PI: −5.9 [0.3] vs. −1.9 [0.6]; MPFID‐EA: −7.9 [0.4] vs. −3.4 [0.6]) and in placebo (MPFID‐PI: −5.4 [0.4] vs. −1.0 [0.5]; MPFID‐EA: −7.1 [0.5] vs. −3.2 [0.5]).
Conclusions
This analysis demonstrated that a greater proportion of patients treated with erenumab reverted from CM to EM compared to patients treated with placebo. The reversion from CM to EM was reflected by the greater improvements in patient‐reported outcomes in the erenumab group.
Plain Language Summary
Chronic migraine (CM) represents a greater burden to patients with migraine; thus, conversion from CM to episodic migraine (EM) by reducing the frequency of monthly headache days can be a good indicator of how well migraine treatment is working. This study evaluated the rate of conversion from CM to EM in two groups of patients, in which one group received erenumab and the other group received placebo. This study showed that more patients in the erenumab group changed from CM to EM and reported improvement in daily activities compared to the placebo group.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38785393</pmid><doi>10.1111/head.14733</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8933-088X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-8748 |
| ispartof | Headache, 2025-01, Vol.65 (1), p.143-152 |
| issn | 0017-8748 1526-4610 1526-4610 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3060380352 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antibodies, Monoclonal, Humanized - pharmacology Asia Asian People Body mass index Body size Calcitonin Calcitonin Gene-Related Peptide Receptor Antagonists - administration & dosage Calcitonin Gene-Related Peptide Receptor Antagonists - pharmacology calcitonin gene–related peptide Chronic Disease Clinical trials Double-Blind Method Effectiveness erenumab Female Headache Headaches Health services Humans Impact tests Impairment Male Middle Aged Migraine Migraine Disorders - drug therapy Monoclonal antibodies Outcome Assessment, Health Care Patients patient‐reported outcomes Placebos Population studies reversion rate Standard error Subgroups |
| title | Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A38%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20erenumab%20on%20the%20reversion%20from%20chronic%20migraine%20to%20episodic%20migraine%20in%20an%20Asian%20population:%20A%20post%20hoc%20analysis%20of%20the%20DRAGON%20study&rft.jtitle=Headache&rft.au=Wang,%20Shuu%E2%80%90Jiun&rft.date=2025-01&rft.volume=65&rft.issue=1&rft.spage=143&rft.epage=152&rft.pages=143-152&rft.issn=0017-8748&rft.eissn=1526-4610&rft_id=info:doi/10.1111/head.14733&rft_dat=%3Cproquest_cross%3E3154577923%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3154577923&rft_id=info:pmid/38785393&rfr_iscdi=true |